Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-cd7 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine

Next Previous
Search
Drug Profile

Anti-cd7 chimeric antigen receptor natural killer cell therapy - PersonGen Biomedicine

Alternative Names: anti-CD7 CAR-pNK cell therapy; CAR-pNK Cell immunotherapy

Latest Information Update: 15 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PersonGen Biomedicine
  • Class CAR-NK cell therapies; Cell therapies; Gene therapies; Immunoconjugates; Immunotherapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Leukaemia; Lymphoma

Most Recent Events

  • 15 Feb 2022 No development reported - Phase-I/II for Leukaemia (Recurrent, Treatment-resistant) in China (Parenteral)
  • 15 Feb 2022 No development reported - Phase-I/II for Lymphoma (Recurrent, Treatment-resistant) in China (Parenteral)
  • 01 Mar 2016 Phase-I/II clinical trials in Leukaemia (Treatment-resistant, Recurrent) in China (Parenteral) (NCT02742727)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top